Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
about
Immune mechanisms of protection: can adjuvants rise to the challenge?Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine developmentVaccine Adjuvants: from 1920 to 2015 and BeyondBeyond empiricism: informing vaccine development through innate immunity researchVaccines for the 21st centuryImmune response to vaccine adjuvants during the first year of lifeDesigning vaccines for the twenty-first century societySquamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelinesA structure-function approach to optimizing TLR4 ligands for human vaccinesAS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice.Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence.Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccineModeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial.A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challengeHow advances in immunology provide insight into improving vaccine efficacy.Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot studyHPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cellsVaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 yearsCharacterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccineAlternative dosage schedules with HPV virus-like particle vaccines.Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.Factors associated with fluctuations in IgA and IgG levels at the cervix during the menstrual cycleEfficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccinesHPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.TLR-based immune adjuvants.An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants.Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteinsA Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral ImmunitySilica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach.Resiquimod and other immune response modifiers as vaccine adjuvants.A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells.High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses.Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean womenHPV - immune response to infection and vaccination
P2860
Q21245319-0268F907-DD5E-464C-93C3-43CC6AC7646DQ21284959-D3C537B8-C700-47CB-8C78-3571875C9437Q26783879-7959F5B3-BCA4-4AB0-B3FA-1DFD0DBF9573Q26824573-8359AC23-9300-4193-8F48-219DC9697642Q27007529-D2192480-32BB-4448-8819-55CF31E26782Q27016633-913AF068-0384-4FC9-8ED7-B925832D9106Q27025703-8BDEE435-EF9B-472F-94BC-DBEAF02087A1Q27686904-4E05A602-4A4E-4B7F-A978-C360DBA4854FQ28818147-6840C9CF-79BC-4A51-A71A-68FB5174C236Q30374665-7A8CEA83-9633-4B06-AC36-1AC5E969BAE1Q30429719-EA351C87-E15E-4453-B504-217CC288CA70Q30430552-5BD30639-B592-46EF-AA40-292A7A220241Q30573204-9A8741A1-ABFE-48FE-A079-530530BABACAQ30980654-967A9C26-3348-48D1-A65B-FAC91590953CQ33579684-B938CEF3-DCC1-4CD0-8ADC-32F405681B7CQ33621078-E77C9314-8BAF-432D-AC38-C880E0890C44Q33896995-42D5BE84-4C92-4FC8-A351-8AF008BBD173Q33929216-7220856A-956A-4D03-ACC9-14CA17875F93Q34011491-5B8E8411-79EC-4E93-BE53-ED3CFCDBEF87Q34014798-F4743FD3-0A3B-4433-B05F-F81AAF337CE8Q34032367-3CB3BA0F-BD07-4C40-AE43-599207B74FEAQ34102466-F592102F-3F5C-49F4-8909-A3468796FBE7Q34120040-C58659D1-D32C-4FA0-B40B-4BE1F4986B9DQ34154315-B009C15D-80DB-426B-B263-CD9599B3536EQ34199560-4D6B3AE8-AAF8-46CC-9914-B8C7D4ACD497Q34290717-CABDFCCE-8722-40D3-BCD0-F4C05A802ED7Q34335370-DB942EE1-EEE8-4B55-BCE6-8043BF684E1AQ34400322-D33916A6-1FD2-449B-AC3B-E088D1011C1BQ34431983-78DBF3E2-8F10-4703-B870-0131AD7069F3Q34466125-5398EC8A-C643-43A3-B166-F85B005722A4Q34492140-152762BC-FBDC-4820-B930-F65BD68729D5Q34520389-3537E98B-4000-45DB-B8CF-4EC92DC5853EQ34600988-24D36617-C101-48B3-81A7-F3922FEF381EQ34631422-A78F26FD-2BC7-48C3-A66B-9E4F17E4DAF6Q34700325-85B62D85-DDC0-423A-A4A8-CA6BA34EFB58Q34708325-762AA258-2155-4949-8EF0-578F216CF565Q34977848-B3243451-1F9F-402F-B932-F259EC534711Q35016793-3EB6E248-D125-4FDE-8563-76D771EC7CC2Q35154517-17AFE9BB-2BF5-4884-B92E-B83CAC610C11Q35180148-4E5BE5B0-3259-455F-9976-64B3C8463B20
P2860
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Enhanced humoral and memory B ...... mpared to aluminium salt only.
@ast
Enhanced humoral and memory B ...... mpared to aluminium salt only.
@en
Enhanced humoral and memory B ...... MPL/aluminium salt combination
@nl
type
label
Enhanced humoral and memory B ...... mpared to aluminium salt only.
@ast
Enhanced humoral and memory B ...... mpared to aluminium salt only.
@en
Enhanced humoral and memory B ...... MPL/aluminium salt combination
@nl
prefLabel
Enhanced humoral and memory B ...... mpared to aluminium salt only.
@ast
Enhanced humoral and memory B ...... mpared to aluminium salt only.
@en
Enhanced humoral and memory B ...... MPL/aluminium salt combination
@nl
P2093
P1433
P1476
Enhanced humoral and memory B ...... mpared to aluminium salt only.
@en
P2093
Brigitte Colau
Emmanuel Hanon
Francis Dessy
Gary Dubin
Genevieve Losonksy
Joann Suzich
Marc A Fourneau
Marcelle Van Mechelen
Marie-Thérèse Martin
Martine A Wettendorff
P304
P356
10.1016/J.VACCINE.2006.06.005
P407
P577
2006-06-19T00:00:00Z